Improving Molecular Biomarker Reporting

Molecular biomarker reports often rely on the oncologist knowing the significance of a specific somatic variant in a particular disease, and what drug targets/therapies may be efficacious. Providing a user-friendly biomarker report which effectively communicates variant clinical significance in the context of disease, other variants, and level of evidence supporting variant impact on pathogenicity is challenging. Best practices are needed for biomarker reporting, which optimally presents molecular profiling results for efficient interpretation by oncologists. AMP has led other efforts to standardize oncology variant interpretation and reporting guidelines in collaboration with other professional organizations and stakeholder representatives. 

"Oncologist-friendly” Molecular Biomarker Reports  

AMP convened a subject matter expert working group with representation from American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) to develop a consensus provider-friendly (i.e., “oncologist-friendly”) next-generation sequencing (NGS) molecular biomarker report template focused on specific report elements, including format and content details. Complete project details will be available in [Gibson et al., 2024] (to be published).

Template with Table (PDF)

Template without Table (PDF)

Mock NSCLC Report (PDF) 

An implementation survey will follow on-demand CME education about the “oncologist-friendly” molecular biomarker report template in one year to determine community template uptake. The team will make revisions to the template based on this feedback and communicate them to the public, along with a revised template.  

View CME Webinar (TBD) 

VIEW 2023 AMP Annual Meeting & Expo Session (non-CME) 

This project is supported by unrestricted educational grant funding  

from AstraZeneca and Daiichi Sanyko, Inc.